Omiics

Omiics ApS is a research-based service provider and consultancy company within the field of Next Generation Sequencing (NGS).
Linkedin

Omiics ApS is a research-based service provider and consultancy company within the field of Next Generation Sequencing (NGS). Omiics was founded in July 2018 as a biotechnology spin-out from Aarhus University, Denmark. The start-up was facilitated by participation in EU-FP7 EpimiRNA. The experienced staff that make up omiics are long time experts in NGS and related laboratory and bioinformatics techniques, ensuring high standards and research-based consultancy on NGS related matters. Omiics provides complete NGS and bioinformatics projects for customers in research at universities, hospitals and industry across Europe. The focus is on performing NGS projects tailored to specific needs and material, enabling non-standard high-tech studies.

In the laboratory, we provide flexible experimental design tailored to the available non-standard sample material. With our bioinformatic capabilities we provide customer-centered services which specifically address the customer’s research questions. Altogether making a product of high quality easily accessible to our customers with end-to-end support.

Interest and Role in the Project

Omiics will use their expertise in low input RNA sequencing and bioinformatics analysis

For the current project, omiics will use their expertise in low input RNA sequencing and bioinformatics analysis to assist the development a of tRNA fragment sensitive cellular system for GDNF release. RNA sequencing is an ideal method for measuring tRNA fragments and full gene transcriptomes to assay the impact of GDNF release. The main effort by omiics will be in sequencing and analysing patient samples to guide the optimal gating strategy and strengths of the implanted device. Correct gating is crucial for the function of the device produced in this consortium. The current project is a unique opportunity for omiics to use their specialized expertise to further epilepsy treatment and to collaborate with highly competent international experts.